Travere Therapeutics recently reached a new 52-week high after investors reacted to regulatory updates for its rare kidney disease therapy FILSPARI, including the removal of an FDA advisory committee ...
New York, USA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Focal Segmental Glomerulosclerosis Clinical Trial Pipeline Analysis Demonstrates 12+ Key Companies at the Horizon Expected to Transform the Treatment ...
DelveInsight’s “Focal Segmental Glomerulosclerosis Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding of the Focal Segmental Glomerulosclerosis, ...
"Focal Segmental Glomerulosclerosis Pipeline Insights"DelveInsight's,“Focal Segmental Glomerulosclerosis- Pipeline Insight, 2025” report provides comprehensive insights about 15+ companies and 18+ ...
The global focal segmentmental glomerulosclerosis (FSGS) treatments market sales is expected to expand at a compound annual growth rate (CAGR) of 5% between 2023 and 2033, from US$ 3 billion in 2023 ...
Please provide your email address to receive an email when new articles are posted on . Researchers identified functionally relevant risk factors for pediatric primary focal segmental ...
Steroid-resistant nephrotic syndrome (SRNS) represents glomerular disease resulting from a number of different etiologies leading to focal segmental glomerulosclerosis (FSGS). Recently, many genes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback